ArticleFrontiers in pharmacology2026
Artificial intelligence-driven prediction and design of cell-penetrating peptides for advanced drug delivery system.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cell-penetrating peptides (CPPs) are promising delivery vectors for transporting therapeutic agents across cellular membranes. However, their rational design remains challenging because the relationship between peptide sequence and translocation efficiency is highly complex and nonlinear. Methods: In this study, we developed an artificial intelligence-driven framework that integrates biochemical rules derived from large language models (LLMs) with conventional peptide descriptors for CPP prediction and design. Interpretable rules extracted from GPT-4o and DeepSeek were encoded as binary feature vectors and combined with sequence-based descriptors to construct hybrid machine learning models. Model performance was evaluated on the benchmark CPP924 dataset using repeated stratified cross-validation, and the optimized models were further used for Results: The top-performing hybrid classifier achieved a cross-validated accuracy of 0.91 ± 0.03 (best single held-out split, 0.94) on the CPP924 dataset. The LLM-derived rules outperformed conventional physicochemical and fingerprint descriptors and matched amino-acid composition; integrating the rule and composition features yielded the best overall classifier. Using the optimized RF-GPT-Fre and RF-DS-Fre models, we generated six Conclusion: These findings demonstrate that combining LLM-derived biochemical knowledge with machine learning improves interpretable CPP prediction and candidate prioritisation. This study provides a reproducible computational strategy for peptide engineering and establishes a basis for the experimental evaluation of next-generation drug-delivery vehicles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.